Updated Xarelto data convinces NICE

 NICE has changed its original decision on the use of Xarelto (rivaroxaban) as an option for deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism (PE).

The Institute now recommends Xarelto’s use in final draft guidance after Bayer supplied requested data on the long-term clinical and cost effectiveness of the treatment.

Professor Carole Longson, NICE Health Technology Evaluation Centre Director, said the “additional information and analysis” convinced NICE’s Appraisal Committee.

Earlier this year in March, NICE issued draft guidance that failed to recommend Xarelto after concerns were raised about its use in the context of UK clinical practice.

However, Bayer supplied the requested information on patients who were assigned treatment durations of 3, 6 and 12 months and data on the drug’s cost effectiveness compared to existing options.

As a result, the Committee concluded that Xarelto is more clinically and cost effective than enoxaparin followed by a vitamin K antagonist for preventing recurrent VTE in people in whom treatment for up to 12 months is indicated.

There are believed to be more than 46,000 cases of acute DVT in England and Wales with that figure expected to rise to nearly 50,000 by 2016 due to the ageing population.

Xarelto was recently shortlisted for the globally acclaimed Prix Galien medal.